Apogee Therapeutics, Inc. (APGE)
| Market Cap | 6.20B +188.2% |
| Revenue (ttm) | n/a |
| Net Income | -255.84M |
| EPS | -4.22 |
| Shares Out | 74.70M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 689,431 |
| Open | 82.76 |
| Previous Close | 81.81 |
| Day's Range | 82.06 - 84.15 |
| 52-Week Range | 34.34 - 95.32 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 112.00 (+34.89%) |
| Earnings Date | May 12, 2026 |
About APGE
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for APGE stock is "Strong Buy." The 12-month stock price target is $112.0, which is an increase of 34.89% from the latest price.
News
Apogee Therapeutics initiated with a Buy at Rothschild & Co Redburn
Rothschild & Co Redburn analyst Qize Ding initiated coverage of Apogee Therapeutics (APGE) with a Buy rating and $140 price target The firm has a “bullish view” on APG777 into
Apogee Therapeutics price target raised to $110 from $105 at Mizuho
Mizuho raised the firm’s price target on Apogee Therapeutics (APGE) to $110 from $105 and keeps an Outperform rating on the shares. The firm cites last week’s 52-week data for
Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million
SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential fo...
Apogee Therapeutics 5M share Secondary priced at $70.00
Jefferies, TD Cowen, Stifel and Guggenheim acted as joint book running managers for the offering.
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, March 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential fo...
Apogee Therapeutics price target raised to $118 from $108 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Apogee Therapeutics (APGE) to $118 from $108 and keeps a Buy rating on the shares. The firm says zumilokibart posted “credible” doses
Apogee Therapeutics price target raised to $160 from $130 at Guggenheim
Guggenheim analyst Seamus Fernandez raised the firm’s price target on Apogee Therapeutics (APGE) to $160 from $130 and keeps a Buy rating on the shares after zumilokibart Phase 2 Part
Apogee Therapeutics price target raised to $125 from $95 at Citi
Citi raised the firm’s price target on Apogee Therapeutics (APGE) to $125 from $95 and keeps a Buy rating on the shares. The firm believes the Phase 2a data further
Apogee Therapeutics price target raised to $130 from $89 at Canaccord
Canaccord analyst Edward Nash raised the firm’s price target on Apogee Therapeutics (APGE) to $130 from $89 and keeps a Buy rating on the shares. The firm raised its target
Apogee Therapeutics announces $300M common stock offering
Apogee Therapeutics (APGE) announced that it has commenced an underwritten public offering of $300M of shares of its common stock. Apogee intends to use the net proceeds from this offering,
Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering
SAN FRANCISCO and BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential fo...
Apogee Therapeutics rises 22.9%
Apogee Therapeutics (APGE) is up 22.9%, or $15.14 to $81.18.
Apogee Therapeutics price target raised to $131 from $99 at BofA
BofA raised the firm’s price target on Apogee Therapeutics (APGE) to $131 from $99 and keeps a Buy rating on the shares after the company shared 52-week maintenance data from
Apogee Therapeutics rises 17.9%
Apogee Therapeutics (APGE) is up 17.9%, or $11.82 to $77.86.
Why Did Apogee Therapeutics Stock (APGE) Soar Today?
Apogee Therapeutics stock gained on Monday alongside strong results from the company’s latest clinical trial.
Apogee Therapeutics price target raised to $120 from $95 at Wedbush
Wedbush raised the firm’s price target on Apogee Therapeutics (APGE) to $120 from $95 and keeps an Outperform rating on the shares. Apogee’s zumilokibart met the firm’s “best case” scenario
Apogee data further derisk zumilokibart path to approval, says Stifel
After Apogee Therapeutics (APGE) reported a 52-week data update from the Phase 2a study of zumilokibart in atopic dermatitis, Stifel analyst Alex Thompson contends that these data further derisk zumil...
Apogee Therapeutics Transcript: Study result
The phase II APEX Part A study showed zumilokibart maintained and deepened efficacy in atopic dermatitis over 52 weeks with both three- and six-month dosing, offering strong lesion and itch control and a favorable safety profile. Reduced injection frequency addresses key patient needs and positions the drug as a potential first-line therapy.
Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis
APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including: - 75% and 85% patients maintained EASI-75 - 86% and 78% patients ma...
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
SAN FRANCISCO and BOSTON, March 22, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for be...
Apogee Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Upcoming maintenance data aims to validate quarterly and semi-annual dosing for atopic dermatitis, with phase 3 trials launching this year and full funding secured through 2028. Market research supports strong uptake potential, and expansion into asthma, EoE, and combination therapies is planned.
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway: - APEX Phase 2 Part A 52-week data expected this month - APEX Phase 2 Part B 1...
Apogee Therapeutics to Participate in Upcoming March Conferences
SAN FRANCISCO and BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the TD Cowen 46t...
Apogee Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Recent data show rapid itch relief and durable efficacy in atopic dermatitis and asthma, with a focus on extending dosing intervals and maintaining a strong safety profile. Plans include a 2029 launch, label expansion, and development of combination therapies to address broader inflammatory conditions.
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim E...